FUNDAMENTALS |
MarketCap: |
3.17 mill
|
EPS: |
-2.50
|
P/E: |
-0.0300
|
Earnings Date: |
Mar 28, 2024 |
SharesOutstanding: |
39.62 mill
|
Avg Daily Volume: |
8.56 mill
|
RATING
2024-03-28 |
B
|
Neutral
|
RATINGS |
Rating CashFlow: |
Strong Buy
|
|
Return On Equity: |
Strong Sell
|
|
Return On Asset: |
Strong Sell
|
|
DE: |
Neutral
|
|
P/E: |
Neutral
|
|
Price To Book: |
Buy
|
|
QUARTER GROWTHS |
|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 |
Revenue | n/a | n/a | n/a | | | |
Gr.Profit | n/a | n/a | | | | |
Ebit | | | | | | |
Asset | | | | | | |
Debt | | | | | | |
PE RATIO: COMPANY / SECTOR |
0.00x
|
Company: PE -0.0300 | sector: PE -3.05
|
PE RATIO: COMPANY / INDUSTRY |
-0.01x
|
Company: PE -0.0300 | industry: PE 5.88
|
DISCOUNTED CASH FLOW VALUE |
N/A
|
N/A
|
Expected Trading Range (DAY) |
$ 0.0480 - 0.112
( +/- 40.00%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2023-10-19 | Baker Bros. Advisors Lp | Sell | 251 902 | Class A common stock |
2023-10-19 | Baker Bros. Advisors Lp | Sell | 22 837 | Class A common stock |
2023-09-17 | Ruiz Roger Richard | Sell | 0 | Class A Common Stock |
2023-09-17 | Ruiz Roger Richard | Sell | 27 000 | Employee stock option (right to buy) |
2023-09-17 | Ruiz Roger Richard | Sell | 25 000 | Employee stock option (right to buy) |
INSIDER POWER |
31.01
|
Last
95 transactions |
Buy:
4 503 145 | Sell:
1 985 486 |
Forecast:
16:00 - $0.0800
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.0800
Forecast 2: 16:00 - $0.0800
Forecast 3: 16:00 - $0.0800
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
MACD |
|
Volume Signals |
Price |
$0.0800 (6.67% )
|
Volume |
0.0812 mill
|
Avg. Vol. |
8.56 mill
|
% of Avg. Vol |
0.948 %
|
Signal 1: |
|
Signal 2: |
|
Last 10 Buy & Sell Signals For BCEL
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date |
Signal |
@ |
Closed |
% |
Feb 8 - 15:29 | buy | $0.268 | N/A | Active |
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.